title: Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly.
authors.affiliation: Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Peter Q
authors.initials: PQ
authors.lastname: Eichacker
authors.forename: Charles
authors.initials: C
authors.lastname: Natanson
authors.forename: Robert L
authors.initials: RL
authors.lastname: Danner
mesh_terms: D002986:Clinical Trials as Topic; D017277:Drug Approval; D004345:Drug Industry / Q000191:economics; D006801:Humans; D040541:Marketing; D017410:Practice Guidelines as Topic; D011486:Protein C / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012109:Research Support as Topic; D018805:Sepsis / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated